Key result
Leuprorelin-based ADT carries a ~4% 1-year MACE risk regardless of prior cardiovascular disease.
Why the study?
The efficacy and cardiovascular safety of leuprorelin-based androgen deprivation therapy in routine practice for patients with locally advanced and metastatic hormone-sensitive prostate cancer were not well characterized.
Cohort (n=1,372)
Yes
Leuprorelin-based androgen deprivation therapy demonstrated a low incidence of cardiovascular events in a real-world cohort of patients with hormone-sensitive prostate cancer.
INTRODUCTION: LEAN is a prospective, multicenter, noninterventional, German cohort study in patients with locally advanced and metastatic hormone-sensitive prostate cancer (PC). This analysis explores the efficacy and safety of leuprorelin in patients with PC and an indication for androgen deprivation therapy (ADT) in routine practice. METHODS: Safety assessment focused on the incidence of major adverse cardiovascular (CV) events (MACEs; a composite of all-cause death, myocardial infarction, or stroke) over the 12-month study period. Patients initiating ADT before enrollment were excluded from the analysis. RESULTS: Of the 1,372 patients included, MACEs occurred in 57 (4.2%) patients and in 18/532 (3.4%) versus 39/840 (4.6%) patients without and with a pre-existing CV comorbidity, respectively (p = 0.264). Of the 57 MACEs, 17 were CV events and 20 were considered PC-related events; in 20 patients, events were classed as "other" or the context remained unknown. Only one MACE, nonserious arrhythmia, was considered drug related by the urologist. Of the 52 deaths reported in patients with MACEs, 12 were related to a CV event and 20 were related to disease progression. CONCLUSION: In a large European patient cohort, leuprorelin-based ADT demonstrated an acceptable safety profile, with a low incidence of CV events.
No takes yet. Share an insight, caveat, or question.
Schmitz‐Dräger et al. (2025) conducted a cohort in locally advanced and metastatic hormone-sensitive prostate cancer (n=1,372). leuprorelin was evaluated on major adverse cardiovascular (CV) events (MACEs; a composite of all-cause death, myocardial infarction, or stroke). Leuprorelin-based androgen deprivation therapy resulted in a 4.2% incidence of MACE at 12 months, with rates of 4.6% vs 3.4% in patients with and without prior CV comorbidity (p=0.264).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: